Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2008 Jan;93(1):19-25. Epub 2007 Nov 6.

Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.

Author information

1
Department of Endocrinology, Vrije Universiteit University Medical Center, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands. ljgooren@truemail.co.th

Abstract

CONTEXT:

Transsexuals receive cross-sex hormone treatment. Its short-term use appears reasonably safe. Little is known about its long-term use. This report offers some perspectives.

SETTING:

The setting was a university hospital serving as the national referral center for The Netherlands (16 million people).

PATIENTS:

From the start of the gender clinic in 1975 up to 2006, 2236 male-to-female and 876 female-to-male transsexuals have received cross-sex hormone treatment. In principle, subjects are followed up lifelong.

INTERVENTIONS:

Male-to-female transsexuals receive treatment with the antiandrogen cyproterone acetate 100 mg/d plus estrogens (previously 100 microg ethinyl estradiol, now 2-4 mg oral estradiol valerate/d or 100 microg transdermal estradiol/d). Female-to-male transsexuals receive parenteral testosterone esters 250 mg/2 wk. After 18-36 months, surgical sex reassignment including gonadectomy follows, inducing a profound hypogonadal state.

MAIN OUTCOME MEASURES:

Outcome measures included morbidity and mortality data and data assessing risks of osteoporosis and cardiovascular disease.

RESULTS:

Mortality was not higher than in a comparison group. Regarding morbidity, with ethinyl estradiol, there was a 6-8% incidence of venous thrombosis, which is no longer the case with use of other types of estrogens. Continuous use of cross-sex hormones is required to prevent osteoporosis. Androgen deprivation plus an estrogen milieu in male-to-female transsexuals has a larger deleterious effect on cardiovascular risk factors than inducing an androgenic milieu in female-to-male transsexuals, but there is so far no elevated cardiovascular morbidity/mortality. Low numbers of endocrine-related cancers have been observed in male-to-female transsexuals.

CONCLUSIONS:

Cross-sex hormone treatment of transsexuals seems acceptably safe over the short and medium term, but solid clinical data are lacking.

PMID:
17986639
DOI:
10.1210/jc.2007-1809
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center